Houghton, P. J., Maris, J., Friedman, H. S., Kier, S. T., Lock, R. B., Gorlick, R., … Smith, M. A. (2006). Evaluation of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, KOS-1022) against Childhood Cancer Models by the Pediatric Preclinical Testing Program (PPTP). In CANCER RESEARCH (Vol. 66). AMER ASSOC CANCER RESEARCH.

Houghton, Peter J., John Maris, Henry S. Friedman, Stephen T. Kier, Richard B. Lock, Richard Gorlick, E Anders Kolb, C Patrick Reynolds, Christopher Morton, and Malcolm A. Smith. “Evaluation of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, KOS-1022) against Childhood Cancer Models by the Pediatric Preclinical Testing Program (PPTP).” In CANCER RESEARCH, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.

Houghton PJ, Maris J, Friedman HS, Kier ST, Lock RB, Gorlick R, et al. Evaluation of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, KOS-1022) against Childhood Cancer Models by the Pediatric Preclinical Testing Program (PPTP). In: CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2006.

Houghton, Peter J., et al. “Evaluation of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, KOS-1022) against Childhood Cancer Models by the Pediatric Preclinical Testing Program (PPTP).” CANCER RESEARCH, vol. 66, no. 8, AMER ASSOC CANCER RESEARCH, 2006.

Houghton PJ, Maris J, Friedman HS, Kier ST, Lock RB, Gorlick R, Kolb EA, Reynolds CP, Morton C, Smith MA. Evaluation of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, KOS-1022) against Childhood Cancer Models by the Pediatric Preclinical Testing Program (PPTP). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2006.